because the reestablishment of coronary blood flow is believed to be central to the benefit of thrombolytic therapy , the u.s. evaluation program of anistreplase has focused on reperfusion , patency , and reocclusion comparisons with approved thrombolytic regimens , including ( 1 ) intracoronary streptokinase ( completed ) ( team-i ) , ( 2 ) intravenous streptokinase ( completed ) ( team-ii ) , and ( 3 ) intravenous tissue plasminogen activator complex or alteplase ( tpa , ongoing ) ( team-iii ) .
C0078956
anistreplase
C0038418
streptokinase